Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, announced the upcoming presentation of initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a bispecific ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with clear cell renal cell carcinoma (ccRCC) in a poster at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, being held October 22-26, 2025 in Boston, Massachusetts.

Xencor management also became aware that an investment bank published takeaways from the abstract accepted for presentation at the conference, which is not publicly available via the conference website or app. Full abstracts are scheduled to be released by the conference next Wednesday, October 22 at 12 p.m. ET.

Xencor submitted a placeholder abstract with limited detail based on a previous data-cut from the ongoing dose-escalation study of XmAb819 (Clinicaltrials.gov Identifier: NCT05433142). The abstract contained a high-level safety summary across all dosing cohorts with no additional information regarding efficacy beyond what had been previously disclosed during a public webcast in September 2024.

Presentation of a dataset from an updated data-cut at the conference will include a detailed safety analysis along with efficacy results from the target dose range when the embargo lifts. Management will also host a webcast and conference call to discuss the results and will provide access credentials for the event on a later date.